BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Pompilia Ispas-Szabo, Mihaela Maria Friciu, Phuong Nguyen, Yves Dumoulin, Mircea Alexandru Mateescu. Novel self-assembled mesalamine–sucralfate complexes: preparation, characterization, and formulation aspectsDrug Development and Industrial Pharmacy 2016; 42(7): 1183 doi: 10.3109/03639045.2015.1118493
2
Lee Ann Hodges. Multiparticulate Drug DeliveryAdvances in Delivery Science and Technology 2017; : 359 doi: 10.1007/978-1-4939-7012-4_14
3
Aurelio Romero-Castro, Mara Gutiérrez-Sánchez, José Correa-Basurto, Martha Cecilia Rosales Hernández, Itzia Irene Padilla Martínez, Jessica Elena Mendieta-Wejebe, Mária A. Deli. Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory ActivityPLOS ONE 2016; 11(7): e0159889 doi: 10.1371/journal.pone.0159889
4
Satohiro Masuda, Yuki Yamamoto. Drug delivery system in treatment against inflammatory bowel disease: present and futureDrug Delivery System 2018; 33(5): 397 doi: 10.2745/dds.33.397
5
Kousaku Kawashima, Shunji Ishihara, Takafumi Yuki, Koji Onishi, Yoshinori Kushiyama, Hirofumi Fujishiro, Youichi Miyaoka, Mika Yuki, Yoshinori Komazawa, Takashi Tanimura, Hiroki Sonoyama, Yasumasa Tada, Ryusaku Kusunoki, Akihiko Oka, Nobuhiko Fukuba, Naoki Oshima, Ichiro Moriyama, Yoshikazu Kinoshita. Therapeutic Efficacy of pH-Dependent Release Formulation of Mesalazine on Active Ulcerative Colitis Resistant to Time-Dependent Release Formulation: Analysis of Fecal Calprotectin ConcentrationBioMed Research International 2014; 2014: 1 doi: 10.1155/2014/342751
6
Alvaro Goyanes, Grace B. Hatton, Hamid A. Merchant, Abdul W. Basit. Gastrointestinal release behaviour of modified-release drug products: Dynamic dissolution testing of mesalazine formulationsInternational Journal of Pharmaceutics 2015; 484(1-2): 103 doi: 10.1016/j.ijpharm.2015.02.051
7
Dorota Haznar-Garbacz, Grzegorz Garbacz, Werner Weitschies. Development of oral foams for topical treatment of inflammatory bowel diseaseJournal of Drug Delivery Science and Technology 2019; 50: 287 doi: 10.1016/j.jddst.2019.01.022
8
Maya Olaisen, Olav Spigset, Arnar Flatberg, Atle van Beelen Granlund, Wenche Rødseth Brede, Grethe Albrektsen, Elin Synnøve Røyset, Bodil Gilde, Arne Kristian Sandvik, Tom Christian Martinsen, Reidar Fossmark. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitisAlimentary Pharmacology & Therapeutics 2019; 49(10): 1301 doi: 10.1111/apt.15227
9
Maricelma da Silva Soares de Souza, Sandra Maria Barbalho, Ricardo de Alvares Goulart, Antonely de Cássio Alves de Carvalho. The Current and Future Role of Drugs and Probiotics in the Management of Inflammatory Bowel DiseaseJournal of Biosciences and Medicines 2015; 3(08): 76 doi: 10.4236/jbm.2015.38008
10
Solmaz Zakhireh, Mehrdad Mahkam, Mehdi Yadollahi, Saeed Jafarirad. Investigation of pH-sensitive galactopyranoside glycol hydrogels as effective vehicles for oral drug deliveryJournal of Polymer Research 2014; 21(4) doi: 10.1007/s10965-014-0398-3
11
Yuki Yamamoto, Satohiro Masuda, Hiroshi Nakase, Minoru Matsuura, Shihoko Maruyama, Tadakazu Hisamatsu, Yasuo Suzuki, Kazuo Matsubara. Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and <i>N</i>-Acetylmesalamine in Japanese Patients with Ulcerative ColitisBiological and Pharmaceutical Bulletin 2019; 42(1): 81 doi: 10.1248/bpb.b18-00561
12
Soleiman B. Kashkooli, Mehrdad Rouhani, Fred Saibil. Ultra-high dose of mesalamine to treat steroid-dependent ulcerative colitisJournal of Crohn's and Colitis 2014; 8(12): 1745 doi: 10.1016/j.crohns.2014.08.007
13
Adeyinka Abinusawa, Srini Tenjarla. Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH LevelsAdvances in Therapy 2015; 32(5): 477 doi: 10.1007/s12325-015-0206-4
14
O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya, A. I. Parfenov. The effectiveness of mesalazine therapy of ulcerative colitis of moderate severity in real clinical practiceMedical Council 2019; (14): 80 doi: 10.21518/2079-701X-2019-14-80-86